The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck

Melissa A Wilson; Leslie A Fecher

doi:10.1016/j.otc.2020.11.006

The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck

Otolaryngol Clin North Am. 2021 Apr;54(2):329-342. doi: 10.1016/j.otc.2020.11.006. Epub 2021 Feb 15.

Authors

Melissa A Wilson¹, Leslie A Fecher²

Affiliations

¹ Sidney Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA.
² University of Michigan, Rogel Cancer Center, C343 MIB, 1500 East Medical Center Drive, SPC 5848, Ann Arbor, MI 48109-5848, USA. Electronic address: lfecher@med.umich.edu.

PMID: 33602512
DOI: 10.1016/j.otc.2020.11.006

Abstract

The treatment of advanced melanoma has changed dramatically over the last decade. With the discovery of activating BRAF mutations and the development of targeted therapies and checkpoint inhibitors, the overall survival of patients with advanced melanoma has improved. This article provides an overview of systemic therapies, including the pivotal agents that have led to these advances.

Keywords: BRAF; Checkpoint inhibitor; Immunotherapy; MEK; Melanoma.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Melanoma* / drug therapy
Molecular Targeted Therapy
Proto-Oncogene Proteins B-raf / genetics
Proto-Oncogene Proteins B-raf / therapeutic use
Skin Neoplasms* / drug therapy

Substances

Proto-Oncogene Proteins B-raf